• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Two years in, the team at Nous­Com bags $49M to fund first hu­man stud­ies of neoanti­gen drugs

8 years ago
Financing
Startups

Shoot­ing for a new stan­dard on os­teoarthri­tis, Mer­ck KGaA out­lines promis­ing da­ta for a po­ten­tial game-chang­er

8 years ago
R&D

Peer Re­view: aTyr pro­motes da­ta ex­pert San­jay Shuk­la as CEO

8 years ago
Peer Review

For­mer Puma ex­ec agrees to prison time, penal­ty on in­sid­er trad­ing case; Ex-GSK boss Wit­ty to lead UK’s new ...

8 years ago
News Briefing

Feds charge Osiris ex­ecs with cook­ing the books as stock price soared

8 years ago
People

GSK R&D chief Val­lance is out as its new CEO changes di­rec­tion un­der a new crew

8 years ago
People

Is Neu­ro­crine primed for takeover? Rev­enue soars on In­grez­za sales

8 years ago
Pharma

No­var­tis and Am­gen launch new Alzheimer's study

8 years ago
R&D
Discovery

Valeant fi­nal­ly wins long-de­layed FDA OK for its glau­co­ma drug, which is more good news for Aerie

8 years ago
Pharma

GOP tax re­form bill would re­peal or­phan drug re­search cred­its

8 years ago
Pharma

Prize fight in Paris: Al­ny­lam and Io­n­is slug it out over PhI­II da­ta in prepa­ra­tion for a block­buster show­down

8 years ago
R&D

Fo­cus­ing on next-gen can­cer drugs, GSK touts a ‘break­through’ at FDA; Ais­ling rais­es $280M fund

8 years ago
News Briefing

IPO mar­ket warms with Spero, Al­lena head­ing to Wall Street

8 years ago
Financing

Sanofi scraps a PhII IL4/IL13 de­vel­op­ment pro­gram for lung scar­ring dis­ease

8 years ago
R&D

Mallinck­rodt bags an­oth­er mi­cro­cap biotech, pick­ing up Ocera’s failed drug in $117M buy­out

8 years ago
Deals

Dicer­na and Boehringer part­ner on RNAi treat­ment for NASH

8 years ago
R&D

AveX­is of­fers com­pelling rea­sons for a fast FDA OK for gene ther­a­py to treat spinal mus­cu­lar at­ro­phy in in­fants

8 years ago
R&D
Cell/Gene Tx

Shkre­li out, Cuban in: Twit­ter proves es­sen­tial for biotech rebel Ethan Perl­stein

8 years ago
People
Financing

Agios spot­lights promis­ing da­ta for IDH1 drug, putting it on the path to FDA sub­mis­sion

8 years ago
R&D

FDA pan­el votes yes on In­di­v­ior’s opi­oid ad­dic­tion drug

8 years ago
Pharma

As­traZeneca inks a car­dio drug de­vel­op­ment pact with mR­NA spe­cial­ist Mod­er­na

8 years ago
R&D
Pharma

#ASH17: No­var­tis’ 6-month Kym­ri­ah da­ta in DL­B­CL sets up a head-to-head fight with Gilead

8 years ago
R&D

#ASH17: The big los­er in CAR-T, Juno is mak­ing a bid to seize the fast lane to fron­trun­ner sta­tus

8 years ago
R&D

#ASH17: Blue­bird touts ear­ly signs that its new-and-im­proved sick­le cell gene ther­a­py is work­ing

8 years ago
R&D
Cell/Gene Tx
First page Previous page 1072107310741075107610771078 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.